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Abstract
Background: Despite complete resection, disease-free survival (DFS) of patients with cholangiocarcinoma (CCA) is
less than 65 % after one year and not more than 35 % after three years. For muscle invasive gallbladder carcinoma
(GBCA), prognosis is even worse, with an overall survival (OS) of only 30 % after three years. Thus, evaluation of adjuvant
chemotherapy in biliary tract cancer in a large randomized trial is warranted.
Methods/Design: ACTICCA-1 is a randomized, multidisciplinary, multinational phase III investigator initiated trial. With
respect to data obtained in the ABC-02 trial, we selected the combination of gemcitabine and cisplatin for 24 weeks as
investigational treatment. Based on adjuvant trials in pancreatic cancer with comparable postoperative recovery time,
inclusion of patients within a maximum interval of 16 weeks between surgery and start of chemotherapy was stipulated.
Due to the different prognosis and treatment susceptibility of muscle invasive carcinoma, two separate cohorts (CCA and
GBCA) were included to capture the potentially different treatment effects. Randomization is stratified for lymph
node status for both cohorts and localization for CCA. The primary endpoint is DFS and secondary endpoints include
OS, safety and tolerability of chemotherapy, quality of life, and patterns of disease recurrence. For CCA, adjuvant
chemotherapy should increase DFS 24 months post-surgery from 40 to 55 % to be considered relevant. With a
power of 80 % and a significance level of 5 %, 271 evaluable study patients have to be followed for 24–28 months to
observe 166 events. For GBCA, chemotherapy should increase DFS 24 months post-surgery from 35 to 55 % to be of
relevance; thus, 154 evaluable study patients have to be monitored for 24–28 months to observe 90 events. In both
cohorts, randomization will be 1:1 with chemotherapy for 24 weeks and imaging every twelve weeks. In 2014, the study
was initiated in Germany and in The Netherlands (funded by the Deutsche Krebshilfe, the Dutch Cancer Society, and
supported by medac GmbH). Sites in Australia, Denmark, and the United Kingdom (funded by Cancer Research UK) are
joining 2015.
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Background
Epidemiology of biliary tract cancer
The incidence of biliary tract cancer (BTC) varies extremely
in different geographical regions. In Western countries, the
rate of intrahepatic cholangiocarcinoma (CCA) is low with
0.4 to 1.0 cases per 100,000. The incidence is highest in
patients older than 65 years of age. For unknown reasons,
incidence and mortality rates are increasing within the last
decades in most developed countries. In contrast, hilar
and distal CCA demonstrate only minor regional differ-
ences with incidence rates ranging between 0.5 and 1.1
per 100,000. A slight male predominance is found in pa-
tients with CCA. Cirrhosis, hepatitis B and C, and primary
sclerosing cholangitis are well known risk factors [1–4].
The incidence of gallbladder carcinoma (GBCA) is around
2.0 per 100,000 with a median age at the time of diag-
nosis of 67 years. Gallstones and chronic infections are
important risk factors for GBCA [5, 6].
Outcome after surgical resection
Currently, complete surgical resection represents the only
potentially curative treatment option for CCA and GBCA,
and is therefore the treatment of choice if the respective
tumor is deemed resectable [7]. More than 50 % of pa-
tients present with unresectable disease at the time of
diagnosis. The prognosis at this stage is dismal, being
approximately 3–5 months without intervention [8, 9],
and 6–12 months with palliative chemotherapy (CTx)
[10]. Even after curative resection, 5-year overall survival
(OS) is only 20–40 %. The most relevant prognostic factors
after resection are nodal infiltration, resection margins, vas-
cular invasion, and tumor grading [11–18]. Interestingly,
retrospective analysis showed only a minor role for margin
status (R0 vs. R1) in the prognosis of CCA following resec-
tion, as long as complete tumor clearance is achieved with
modern resection techniques. A recent study evaluated
the results of surgical therapy for intrahepatic CCA, the
incidence, and the management of disease during two se-
quential periods [19]. The 3-year OS was 62 %, whereas
the 3-year disease-free survival (DFS) was only 30 %, the
median OS was 57.1 months. Furthermore, von der Gaag
and colleagues evaluated the long-term outcome of 175
consecutive patients with resected extrahepatic CCA [20].
In this study, the 2-year OS was 50 % and declined to
26 % after five years. In summary, following complete re-
section of CCA, patients had DFS rates of 48 to 65 % after
one year and 23 to 35 % after three years without adjuvant
treatment [12, 17, 21]. Patients with a positive nodal status
(N1) and/or vascular invasion (V1) at time of resection
had an even higher risk of disease recurrence.
For muscle invasive GBCA, prognosis seems to be even
worse [22]. Following complete resection, DFS times are
about 10–12 months and OS rates are about 55 % after
one year and about 30 % after three years [21–24]. A
retrospective Dutch registry study evaluating 368 pa-
tients with GBCA and curative surgery between 2003
and 2008 confirmed these data (1-year OS 56 %, 3-year
OS 26 %) [25].
Treatment modalities for unresectable biliary tract cancer
Potential treatment modalities for unresectable BTC in-
clude CTx, radiotherapy, chemoradiation, photodynamic
treatment, and liver transplantation in localized unresect-
able CCA. Current approaches for systemic, unresectable
BTC, either at initial diagnosis or in case of local or distant
disease progression after resection, are based on systemic
CTx. A previous randomized trial revealed that CTx signifi-
cantly improved survival and quality of life compared to
best supportive care [26]. Several drugs were found to be
active in BTC, e.g., fluorouracil, gemcitabine, mitomycin,
cisplatin, capecitabine, epirubicin, and oxaliplatin. A pooled
analysis of 104 studies evaluating CTx in advanced BTC
suggested that gemcitabine combined with cisplatin or
oxaliplatin achieves the best response rates; however,
without significantly improving survival [27]. The recent
randomized phase III ABC 02 trial revealed a median OS
of 11.7 months among 204 patients treated with gemcita-
bine and cisplatin compared to 8.1 months among 206
patients treated with gemcitabine alone (hazard ratio
0.64, 95 % confidence interval 0.52 to 0.80, p < 0.001).
In addition, median progression-free survival and tumor
control among patients in the gemcitabine/cisplatin-group
was significantly increased (8.0 vs. 5.0 months, p < 0.001;
1.4 % vs. 71.8 %, p = 0.049). Adverse events (AE) were
similar in the two groups, with the exception of more
frequent neutropenia in the gemcitabine/cisplatin-
group, although the number of neutropenia-associated
infections was similar in the two groups [10]. There-
fore, the combination of gemcitabine and cisplatin is
currently regarded as standard of care in metastatic or
unresectable BTC [28].
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Adjuvant chemotherapy for biliary tract cancer
Because of high rates of disease recurrence and poor
survival rates following surgical resection, postoperative
treatment modalities, e.g., CTx, radiotherapy, and che-
moradiation, have been considered to improve patient
survival after resection of BTC [16]. Randomized data
on the efficacy of adjuvant treatment after resection of
BTC are scarce. A multicenter randomized trial evalu-
ated the effect of adjuvant CTx with mitomycin C and
fluorouracil compared to surgery alone for patients with
pancreato-biliary malignancies [21]. In this trial, a non-
significant survival benefit was seen for patients with
adjuvant CTx following R0 resection for CCA with a
DFS at five years of 32.4 % vs. 15.8 % without adjuvant
CTx. In addition, a recent single-institution retrospective
evaluation found that gemcitabine-based adjuvant CTx
after curative intent resection of CCA significantly im-
proved patient survival [15]. Furthermore, a retrospective
analysis of the Surveillance, Epidemiology, and End Re-
sults database showed a significant benefit for adjuvant ra-
diation therapy [29]. Finally, combined chemoradiation
with fluorouracil and mitomycin in 34 patients seemed to
be beneficial compared to historical survival data [30].
The GBCA subgroup of a randomized trial evaluating
fluorouracil and mitomycin compared to observation alone,
showed a significant increase of 8.7 % in the five year DFS
rate in favor of adjuvant CTx in the overall GBCA cohort
consisting of patients after curative and non-curative
surgery [21]. Additionally, adjuvant fluorouracil-based
chemoradiation has been used as adjuvant treatment
after complete or margin-positive resection [23, 24, 31,
32]. Although an effect of adjuvant chemo(radio)therapy
has been suggested for GBCA, randomized data evaluating
current CTx regimens are lacking.
A recent systematic review showed a beneficial impact
of adjuvant treatment in BTC, particularly in patients
with involved lymph nodes or resection margins and dis-
tal or hilar CCA [33]. However, in regard of the paucity
of randomized data (only evaluating fluorouracil and
mitomycin) the derived recommendation in this review
is not without controversy; and thus, current guidelines
recommend inclusion in clinical trials [7, 34]. In addition to
the ACTICCA-1 trial reported in this paper, two studies
are currently underway (recruitment closed, final data
awaited) to investigate the role of adjuvant CTx in patients
with BTC, the French PRODIGE-12 study evaluating Gem-
citbaine and Oxaliplatin (NCT01313377) and the British
BILCAP study employing capecitabine (NCT02170090).
Study rationale
Survival after curative intent resection in BTC is poor due
to high rates of disease recurrence. Data from clinical trials
and retrospective analyses suggest a benefit for adjuvant
treatment. Therefore, the evaluation of adjuvant CTx in
BTC is of high clinical relevance. With respect to current
data obtained in the large randomized phase III ABC 02
trial [10], the combination of gemcitabine and cisplatin for
24 weeks was selected for this clinical trial as experimental
treatment added to the current standard of observation
alone [34]. The chosen stratification factors are based on
currently available data. Intrahepatic vs. hilar and distal
CCA are regarded as different entities of BTC [4]. There-
fore, stratification for this trial was stipulated to exclude
influence of localization. In regard of the different progno-
sis and the potentially different treatment susceptibility of
muscle invasive carcinoma, separate cohorts for CCA and
GBCA were included in the trial design to ensure cap-
turing the potentially different treatment effects for both
entities. Although lymphadenectomy was only recently
added as standard surgical approach, lymph node status
seems to be the most important pathological risk factor
for recurrence, as demonstrated in several studies [11, 15,
17, 33]. A recent large retrospective analysis in 449 pa-
tients with intrahepatic CCA, of whom 248 received
lymph node dissection, demonstrated a significant differ-
ence in OS of 30 vs. 24 months (N0 vs. N1) [35]. Similarly,
lymph node positivity is a strong prognostic factor in
GBCA and was accordingly defined as stratification factor
for this cohort as well [23, 32, 36].
Study objectives
The primary objective of this study is to evaluate the ef-
ficacy of gemcitabine and cisplatin and observation in
terms of DFS compared to observation alone in patients
with BTC after complete surgical resection. The primary
endpoint of this study is DFS and secondary endpoints
include DFS rate 24 months post-surgery (DFSR@24),
OS, safety and tolerability of adjuvant CTx, quality of life
(QoL), function of biliodigestive anastomosis (in terms
of surgical revision, requirement for additional drainage
procedures), rate and severity of biliary tract infections,
patterns of disease recurrence, and locoregional control.
Substudy evaluating the shared decision-making process
New media provide fast and easy access to information and
enhance patient autonomy. Therefore, patients’ competence
concerning the consequences of their disease is growing.
Nevertheless, the information and education provided by
the physician is not replaced, but becomes even more im-
portant. In the doctor-patient relationship, the physician
plays a central role as consultant, who not only offers infor-
mation, but also involves patients in the decision-making
process (shared decision-making). Surveys among onco-
logical patients and physicians on the subject of “shared
decision-making” show differences between physicians’ and
patients’ perspective regarding aims of treatment and in-
volvement in the decision-making process. Therefore, the
quantity and quality of information patients have gained
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after the explanatory discussion and the involvement of pa-
tients in the decision-making process will be investigated in
a substudy in both cohorts of patients with BTC (Fig. 1)
[37, 38].
Methods/Design
The ACTICCA-1 study is a multinational, prospective,
randomized, controlled phase III trial designed to assess
the clinical performance of gemcitabine plus cisplatin
and observation vs. observation alone in patients after
curative intent resection of BTC (Fig. 1). 280 patients
(140 patients per arm) in the CCA cohort and 160 pa-
tients (80 patients per arm) in the GBCA cohort will be
randomized in the treatment phase of the study. Study
enrollment will continue until the indicated number of
patients is reached. Patients withdrawn from the trial for
whatever reason will not be replaced.
Patient selection and randomization
The study contains two different parts, an enrollment
and a treatment phase with different selection criteria.
The focus of the enrollment phase is to collect samples
for translational research and the corresponding pa-
tient data (Fig. 1). Patients will be enrolled into the
trial according to the eligibility criteria for the enrollment
phase (Table 1) and undergo surgical resection with pre-
and postoperative blood sampling and intraoperative tis-
sue sampling. Postoperatively, all enrolled patients are
assessed for eligibility for the treatment phase (Table 2).
Additionally, patients not previously enrolled into the en-
rollment phase for whatever reason (e.g. incidental finding
of CCA or GBCA during surgery) may enter the treatment
phase directly (Fig. 1). These patients have to fulfill the
criteria for the enrollment and the treatment phase
(Table 1 and Table 2).
After inclusion in the treatment phase, patients will
be randomized to arm A or B stratified according to the
following criteria:
 Intrahepatic vs. hilar/distal localization for CCA
 Lymph node positivity vs. negativity for CCA and
GBCA
Treatment
Adjuvant CTx is currently not standard of care for BTC.
Thus, gemcitabine and cisplatin are defined as investiga-
tional medicinal products (IMP) for this study.
Fig. 1 ACTICCA-1 trial design. Legend: BTC, biliary tract cancer; CCA, cholangiocarcinoma; GBCA, gallbladder carcinoma; DFS, disease free survival;
OS, overall survival; QoL, quality of life
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Arm A (gemcitabine plus cisplatin and observation)
Patients assigned to arm A will be followed every three
months and will receive gemcitabine (1000 mg/m2) plus
cisplatin (25 mg/m2) every three weeks on days 1 and 8
intravenously. Treatment with gemcitabine plus cisplatin
will be administered until progression or for a maximum
of eight three-week cycles (24 weeks). In case of recurrent
disease, unacceptable toxicity, or withdrawal of consent,
treatment will be terminated.
Arm B (standard postoperative management)
Patients assigned to arm B will be followed every three
months.
Assessments during the treatment phase
Within four weeks prior to randomization/start of first
treatment
 Review of eligibility criteria
 Relevant medical history and demographics
 Obtain surgical and pathological report
 Physical examination and performance status
according to Eastern Cooperative Oncology Group
(ECOG)
 Laboratory test, including hematology, chemistry
panel and CA 19–9
 Serum pregnancy test (for women of child bearing
potential)
 Quality of life assessment using the European
Organisation for Research and Treatment of Cancer
(EORTC) questionnaire QLQ-C30 and the module
BIL21
 Audiometry (recommended)
 Documentation of disease status by contrast
enhanced abdominal magnetic resonance imaging
(MRI) or computed tomography (CT) and chest CT,
preoperative imaging can be used if performed
within 12 weeks prior to randomization
Follow-up (both arms)
All subjects will be followed every three months for two
years and afterwards 6-monthly for further three years
after randomization. Evaluation for disease recurrence
will be performed by clinical visitation including:
 Physical examination
 Laboratory tests and CA 19–9
 QoL assessment using the EORTC questionnaire
QLQ-C30 and the module BIL21
 Disease assessment (CT or MRI of chest and
abdomen for two years, afterwards abdominal
ultrasound), evaluation according to the revised
Response Evaluation Criteria in Solid Tumors
(RECIST) guideline version 1.1
After disease recurrence, patients will be followed for
survival, disease status, and further therapy (via clinical
visitation or telephone contact).
Table 1 Eligibility criteria for the ACTICCA-1 enrollment phase
• Suspicion of or histologically/cytologically confirmed BTC (intrahepatic,
hilar or distal CCA, or muscle invasive GBCA) scheduled for complete
surgical resection.
• Written informed consent.
• Age >18 years.
• No prior CTx for BTC.
• No previous malignancy within three years or concomitant malignancy,
except non-melanomatous skin cancer or adequately treated in situ
cervical cancer.
• No severe or uncontrolled cardiovascular disease (congestive heart
failure NYHA III or IV, unstable angina pectoris, history of myocardial
infarction in the last three months, significant arrhythmia).
• Absence of psychiatric disorder precluding understanding of
information of trial related topics and giving informed consent.
• No serious underlying medical conditions (judged by the investigator),
that could impair the ability of the patient to participate in the trial.
• Fertile women (<1 year after last menstruation) and procreative men
willing and able to use effective means of contraception (oral
contraceptives, intrauterine contraceptive device, barrier method of
contraception in conjunction with spermicidal jelly or surgically sterile).
• No pregnancy or lactation.
BTC biliary tract cancer, CCA cholangiocarcinoma, CTx chemotherapy, GBCA
gallbladder carcinoma
Table 2 Selection criteria for the ACTICCA-1 treatment phase
• Histologically confirmed BTC (intrahepatic, hilar or distal CCA, or
muscle invasive GBCA) after surgical therapy with macroscopically
complete resection (mixed tumor entities with hepatocellular
carcinoma are excluded).
• Macroscopically complete resection (R0/1) within 6 (−16) weeks before
scheduled start of CTx.
• Performance status according to the ECOG of 0–1.
• Adequate hematologic function: ANC ≥1.5 × 109/L, platelets ≥100 ×
109/L, hemoglobin ≥9 g/dl or ≥5.59 mmol/L.
• Adequate liver function as measured by serum transaminases (AST and
ALT) ≤5 x ULN and bilirubin ≤3 x ULN.
• Adequate renal function, i.e. serum creatinine ≤1.5 x ULN, glomerular
filtration rate≥ 60 mL/min determined with the MDRD formula.
• No active uncontrolled infection, except chronic viral hepatitis under
antiviral therapy.
• No concurrent treatment with other experimental drugs or other
anti-cancer therapy, treatment in a clinical trial within 30 days prior
to randomization.
• Negative serum pregnancy test within 7 days of starting study
treatment in pre-menopausal women and women <1 year after the
onset of menopause (a negative test has to be reconfirmed by a urine
test, should the 7-day window be exceeded).
ANC absolute neutrophil count, BTC biliary tract cancer, CCA cholangiocarcinoma,
CTx chemotherapy, ECOG Eastern Cooperative Oncology Group, GBCA gallbladder
carcinoma, MDRD Modification of Diet and Renal Disease, ULN upper limit
of normal
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Analyses of study endpoints
The two study cohorts will be analyzed for the primary
endpoint (DFS) when 166 events (recurrence or death)
in the CCA cohort and 90 events in the GBCA cohort
have been observed. Follow-up for OS will continue for
up to five years for each individual subject. Time from
randomization to date of first observed disease recur-
rence (either local or distant) or death from any cause (a
second malignancy will not be counted as event in the
DFS analysis) will be utilized to compare DFS. In order
to determine disease recurrence, tumor assessments
(contrast enhanced chest CT and CT or MRI of abdo-
men, serum marker CA 19–9) will be performed every
three months for two years and afterwards every six
months for further three years by abdominal ultrasound
and CA 19–9. In case of clinical suspicion of recurrent
disease and/or CA 19–9 elevation without radiological
tumor recurrence, further examinations must be per-
formed searching for a local recurrence or metastatic
progression of the disease. Diagnosis of recurrence could
either be made by radiological imaging or by positive cy-
tology or histology. OS will be determined as time from
randomization to date of death.
Safety assessments will include physical examination,
performance status (according to ECOG), clinical labora-
tory values, and concomitant medication. All observed
toxicities and side effects will be graded according to
NCI CTCAE 4.03 and the degree of association of each
event with the intervention will be assessed and summa-
rized. Treatment related serious AE (SAE), defined as
SAE considered possibly, probably, or definitely related
to treatment, will be determined. QoL will be assessed
using the EORTC QLQ C30 questionnaire and the mod-
ule BIL21 at baseline and every 12 weeks during follow
up. Function of biliodigestive anastomosis (in terms of
surgical revision, requirement of drainage procedure)
will be assessed during the follow up visits. Severity of
biliary tract infections will be classified according to NCI
CTCAE 4.03. Pattern of recurrence will be classified ac-
cording to distant vs. local recurrence. Local control will
be defined as rate of locoregional failures (local recurrence
or locoregional lymph node metastases). Both endpoints
will be evaluated with regard to the pathological stage
at resection.
Quality assurance and safety
Patient data are collected in electronic case report forms at
the data center of the clinical research organisation (Clin-
ical Trial Center North at the University Medical Center
Hamburg-Eppendorf, Hamburg, Germany). Consistency
checks will be performed on newly entered forms and
queries issued in case of inconsistencies. Monitoring
will be performed according to the respective national
standards. A data safety monitoring board will review
the data on a regular basis.
Statistical considerations and data handling
All patients receiving at least one dose of study treatment
are included in the safety analysis. The intention-to-treat
(ITT) population includes all patients in the study (signed
consent form and confirmation of eligibility). All patients
are grouped according to their randomization, regardless
of treatment received. The primary efficacy endpoint is
DFS in the ITT population.
For CCA, retrospective analyses after R0/R1 resection
showed a DFS@24 of approximately 40 % [12, 15, 17,
19]. Therefore, DFSR@24 is expected to be 40 % without
adjuvant treatment. The IMP (adjuvant gemcitabine and
cisplatin) should increase DFSR@24 by at least 15 % (to
55 %) corresponding to a hazard ratio of 1.563 to be
regarded as promising for further evaluation and of
clinical relevance. The risk of falsely rejecting the null
hypothesis of no difference between the experimental
and the control arm was restricted to 5 %. The risk of
falsely rejecting the alternative hypothesis of a difference
between the experimental and the control arm was se-
lected not to exceed 20 %, corresponding to a power of
80 %. With these restrictions, 271 evaluable study pa-
tients have to be followed for 24–28 months to observe
166 events. With an assumed loss-to-follow-up of 3 %,
280 patients (140 patients per arm) have to be recruited
for inclusion into the trial.
For GBCA, retrospective analyses after R0/R1 resection
showed a DFSR@24 of approximately 35 % [21–24]. There-
fore, DFSR@24 is expected to be 35 % without adjuvant
CTx. The IMP should increase DFSR@24 by 20 % (to
55 %) to be regarded as relevant. Employing the same
statistical restrictions as for CCA, 154 evaluable study
patients have to be followed for 24–28 months to ob-
serve 90 events. With an assumed loss-to-follow-up of
about 4 %, 160 patients (80 patients per arm) have to
be recruited for inclusion into the trial.
Both cohorts are analyzed using the two-sided two-
sample log-rank test, following a group-sequential plan
according to O’Brien and Fleming. This plan provides
one interim analysis after 110 events for the CCA cohort
and after 59 events for the GBCA cohort, and one final
analysis when 166 events in the CCA cohort and 90
events in the GBCA cohort have occurred. For both co-
horts, the interim analyses will have a power of 43.3 % if
the assumed hazard ratio of 1.563 in the CCA cohort
and 1.854 in the GBCA cohort. In both cohorts, the
power increases to 90.4 % if the hazard ratio is 2.
Ethical aspects, trial registration
The ethics committee of the Ärztekammer Hamburg ap-
proved the ACTICCA-1 trial as leading ethics committee
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for all German sites (PVN4571). In addition, local ethics
committees approved the participating German sites (for a
complete list see Additional file 1). For The Netherlands,
the study was approved by the Medisch Ethische Toet-
singscommissie of the Academic Medical Center of the
University of Amsterdam. The trial is registered with Clin-
icalTrials.gov (NCT02170090) and the European Clinical
Trials Database (2012-005078-70).
Funding
The Deutsche Krebshilfe (grant number 110215), the Dutch
Cancer Society, and Cancer Research UK currently fund
the ACTICCA-1 trial. Other international partners are
seeking their own funding sources. For Germany and
The Netherlands, gemcitabine and cisplatin are provided by
medac GmbH (Wedel, Germany). In the United Kingdom,
funding by Cancer Research UK includes the medication.
Biobanking and translational research
Data on prognostic factors for BTC are rare. Moreover,
if adjuvant CTx will become a standard of care in the
future, predictive markers might gain particular import-
ance. Within the current trial, tumor tissue and serum
(both stored locally) will be collected together with the
clinical data. Besides the clinical case report form, an
allocation database will be established gathering the data
of the available patient samples at each study site to enable
translational research. Translational research will be
performed to evaluate the prognostic and predictive im-
pact of different blood and tissue markers in BTC with
particular regard to adjuvant CTx with gemcitabine plus
cisplatin.
Additional file
Additional file 1: List of involved German ethics committees.
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